Hemispherx Fails to Win U.S. Approval for Chronic Fatigue
Hemispherx Biopharma Inc. (HEB), the maker of an injectable medicine for genital warts, failed for the second time to win U.S. approval for a drug to treat chronic fatigue syndrome.
The Food and Drug Administration will require the company to conduct at least one addition clinical trial of the medicine, called Ampligen, complete various nonclinical studies and perform further data analysis, Philadelphia-based Hemispherx said yesterday in a statement. Those with chronic fatigue syndrome are plagued by severe, continued tiredness triggered by an unknown cause, according to the National Institutes of Health.
An FDA advisory panel determined in December that Ampligen hadn’t been proven effective. The agency’s staff raised questions about the company’s lack of safety data on the drug. The FDA rejected the treatment in 2009 and requested more data on its effectiveness.
“The agency stated that the submitted data do not provide substantial evidence of efficacy of Ampligen for the treatment of CFS and that the data do not provide sufficient information to determine whether the product is safe for use in CFS,” Hemispherx said in its statement.
Hemispherx said the data provided are sufficient to establish the drug’s safety and it will request a conference with the FDA to discuss future action.
There are no drugs approved for chronic fatigue syndrome, only those that treat symptoms. Doctors prescribe painkillers, anti-anxiety drugs and antidepressants to help ease symptoms, according to NIH.
The FDA plans a series of activities focused on developing drugs for the syndrome that will help determine how companies can best prove the efficacy of their products. The agency held a teleconference with patients in September, according to the FDA’s website.
To contact the reporter on this story: Anna Edney in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Reg Gale at email@example.com
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.